(Alliance News) -Â Midatech Pharma PLC on Monday reported "encouraging" headline results from a phase one study of MTX110 in patients with Diffuse Intrinsic Pontine Glioma.
Shares in the drug delivery technology company were up 24% at 41.00 pence in London on Monday.
DIPG is a primary brain tumour arising in the middle of the brain stem and cannot be surgically removed.
The primary endpoint of the study was to determine the dosage to be used in a proposed phase two study of the safety and efficacy of MTX110. Preliminary data from the University of California, San Francisco study supports a dose of between 60 micrometers and 90 micrometers of MTX110, depending upon patient tolerance over the course of 12 infusions in phase two.
MTX110 was administered directly into the tumour via a micro-catheter using convection-enhanced delivery with gadolinium-enhanced intra-operative MRI to guide and track drug distribution to the tumour.
"The study has determined a proposed dose range for MTX110 for phase II and has shown that repeated delivery of MTX110 via CED is feasible and safe. In an upcoming phase II study efficacy in this patient population will be assessed," said Sabine Mueller, principal investigator of the UCSF study.
The proposed phase two trial is expected to evaluate overall survival at 12 months as the primary endpoint in 19 evaluable patients.
Steve Damment, executive vice president of Research & Development at Midatech, said: "The overall survival data from this phase I study are encouraging, although further study of MTX110 in DIPG is required to establish whether it can make a difference to these patients and their families."
By Lucy Heming;Â lucyheming@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
